$127.65
1.30% today
Nasdaq, Sep 09, 09:18 pm CET
ISIN
US81663L2007
Symbol
WGS

GeneDx Stock price

$129.33
+24.20 23.02% 1M
+39.67 44.24% 6M
+52.47 68.27% YTD
+95.60 283.43% 1Y
+92.70 253.07% 3Y
-194.07 60.01% 5Y
-194.07 60.01% 10Y
-194.07 60.01% 20Y
Nasdaq, Closing price Mon, Sep 08 2025
-3.21 2.42%
ISIN
US81663L2007
Symbol
WGS

Key metrics

Basic
Market capitalization
$3.7b
Enterprise Value
$3.7b
Net debt
positive
Cash
$134.6m
Shares outstanding
28.7m
Valuation (TTM | estimate)
P/E
3,233.3 | 82.8
P/S
10.3 | 9.0
EV/Sales
10.1 | 8.8
EV/FCF
4,408.4
P/B
13.5
Financial Health
Equity Ratio
58.5%
Return on Equity
-21.3%
ROCE
1.4%
ROIC
1.6%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$362.3m | $414.9m
EBITDA
$26.1m | $54.0m
EBIT
$5.4m | $49.9m
Net Income
$1.4m | $44.9m
Free Cash Flow
$830.0k
Growth (TTM | estimate)
Revenue
48.7% | 35.8%
EBITDA
138.3% | 1,113.8%
EBIT
106.4% | 315.1%
Net Income
101.2% | 185.8%
Free Cash Flow
100.9%
Margin (TTM | estimate)
Gross
67.2%
EBITDA
7.2% | 13.0%
EBIT
1.5%
Net
0.4% | 10.8%
Free Cash Flow
0.2%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
26.3%
Employees
1k
Rev per Employee
$310.0k
Show more

Is GeneDx a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

GeneDx Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a GeneDx forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a GeneDx forecast:

Buy
82%
Hold
18%

Financial data from GeneDx

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
362 362
49% 49%
100%
- Direct Costs 119 119
11% 11%
33%
243 243
78% 78%
67%
- Selling and Administrative Expenses 166 166
12% 12%
46%
- Research and Development Expense 50 50
5% 5%
14%
26 26
138% 138%
7%
- Depreciation and Amortization 21 21
26% 26%
6%
EBIT (Operating Income) EBIT 5.44 5.44
106% 106%
2%
Net Profit 1.41 1.41
101% 101%
0%

In millions USD.

Don't miss a Thing! We will send you all news about GeneDx directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,000 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

Head office United States
Employees 1,000
Website sema4.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today